OctoPlus appoints Jan Hendrik Egberts as CEO
OctoPlus N.V. announced that its Board of Supervisory Directors has hired Jan Hendrik Egberts, M.D. and nominated him for appointment as Chief Executive Officer at the Annual General Meeting of Shareholders in the spring of 2011. He will replace OctoPlus' current CEO Simon Sturge, who will leave the Company as per 1 January 2011 to lead a large division in a top-15 pharmaceutical company. Dr. Egberts will immediately start working together with Mr. Sturge until the end of this year to ensure a smooth transition.
Proposed CEO Jan Hendrik Egberts, M.D. brings over 20 years of experience in the pharmaceutical sector to OctoPlus. He graduated from Erasmus University Medical School in the Netherlands and he pursued the clinical part of his training at Harvard Medical School. He obtained his MBA from Stanford and started his business career in clinical research at Organon Teknika in Belgium. He worked for four years as a strategic consultant to life sciences companies at McKinsey & Company, and from 1994 onwards held business development and general management positions of increasing responsibility in the USA at Merck, Johnson & Johnson and Mölnlycke Health Care. He became CEO of Novadel Pharmaceuticals, Inc. in 2005. Subsequently, Dr. Egberts has served as Senior Advisor in healthcare investments to private equity firm 3i Group and has also gained experience in non-executive positions.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
